Vincent Serra: Beyond Oncology The Expanding Landscape of Immunotherapy
Vincent Serra, Senior Consultant at Biotech Consulting, shared a post on LinkedIn:
“Beyond Oncology: Demystifying the Expanding Immunotherapy Arsenal (Introductory Post)
When we hear ‘immunotherapy,’ we often think of cancer. But harnessing and modulating the human immune system is transforming medicine far beyond oncology from rheumatoid arthritis and multiple sclerosis to asthma, severe allergies, and rare autoimmune conditions.
Today, ‘Immunotherapy’ spans a massive range of targeted biological approaches designed to activate, train, or suppress immune responses.
Here is the breakdown of the major therapeutic modalities shaping modern healthcare:
- Immune Checkpoint Inhibitors (ICIs): Releasing T cell ‘brakes’ in oncology, while checkpoint agonists emerge to quiet autoimmune disease.
- CAR T and Cell Therapies: Reprogramming immune cells to destroy malignant cells in cancer and now resetting the immune system in severe lupus and autoimmune diseases.
- Antibody Drug Conjugates (ADCs): Delivering targeted payloads in oncology, with expanding applications in localized inflammation.
- Bispecific Antibodies and BiTEs: Molecular matchmakers connecting immune cells to targets in both oncology and non oncology (e.g., hemophilia, eye diseases).
- Targeted Monoclonal Antibodies: Blockbusters neutralizing cytokines, receptors, or cell markers in autoimmune, allergic, and infectious conditions.
- Therapeutic Vaccines: Training immune memory against cancer neoantigens, chronic viral infections (HBV, HIV), and neurodegenerative targets.
- Oncolytic Virotherapy and Vector Therapies: Harnessing viral platforms for targeted tumor lysis and gene delivery.
- Cytokines and Immunomodulators: Broad system regulators balancing immunity in both oncology and inflammatory conditions.
Over the coming days, I’ll be breaking down each category and analyzing flagship products across oncology and non oncology, key clinical timelines, market sizing, and the competitive landscape.
Which non oncology application of immunotherapy do you think will see the biggest scientific breakthrough by 2030?
Share your take below!”
Stay updated with Hemostasis Today.
-
Nov 13, 2026, 03:21Abdul Muqtadir Abbasi: Iron Deficiency Beyond Anemia and the Importance of Finding the Cause
-
Nov 13, 2026, 03:05Marc Carrier: Aspirin vs Anticoagulants for VTE Prevention After Joint Replacement
-
Nov 13, 2026, 02:28Julia Sjöberg: ROCK1 Inhibition and Red Blood Cell Recovery After Chemotherapy
-
Nov 13, 2026, 02:07Tonie Reincke: Understanding Deep Vein Thrombosis and Vascular Health
-
Nov 13, 2026, 01:52Akshita Singh: The Remarkable Process of Blood Clotting
-
Nov 12, 2026, 22:52Milka Koupenova: The Role of Platelet RIG-I in Regulating Thrombotic Responses
-
Nov 12, 2026, 22:50Arun V J: Why Has India Still Not Achieved 100% Voluntary Blood Donation?
-
Nov 12, 2026, 22:49Sickle Cell Disease Deserves to Be Prioritised in Ghana – ISCC
-
Nov 12, 2026, 22:47Samir Kumar Beura: Delighted to Serve as a Topic Editor for a Research Topic in Frontiers in Neuroscience